Joann F Gruber1, Sylvia Becker-Dreps1,2, Michael G Hudgens3, M Alan Brookhart1, James C Thomas1,4, Michele Jonsson Funk1. 1. Department of Epidemiology, University of North Carolina (UNC)-Chapel Hill, Chapel Hill, NC. 2. Department of Family Medicine, UNC-Chapel Hill, Chapel Hill, NC. 3. Department of Biostatistics, UNC-Chapel Hill, Chapel Hill, NC. 4. MEASURE Evaluation, Carolina Population Center, UNC-Chapel Hill, NC.
Abstract
BACKGROUND: Altering rotavirus vaccine schedules may improve vaccine performance in low- and middle-income countries. We analyzed data from clinical trials of the monovalent (RV1) and pentavalent (RV5) rotavirus vaccines in low- and middle-income countries to understand the association between vaccine dose timing and severe rotavirus gastroenteritis incidence. METHODS: We assessed the association between variations in rotavirus vaccine administration schedules and severe rotavirus gastroenteritis risk. We used the complement of the Kaplan-Meier survival estimator to estimate risk differences for different schedules. To adjust risk differences (RDs) for confounding, we calibrated estimates in the vaccinated arm using estimates from the placebo arm. RESULTS:There were 3,114 and 7,341 children included from the RV1 and RV5 trials, respectively. The 18-month adjusted severe rotavirus gastroenteritis risk was 4.0% (95% confidence interval [CI] = 1.1, 7.1) higher for those receiving their first RV5 dose at <6 versus ≥6 weeks. For RV1, there was a 4.0% (95% CI = 0.0, 8.2) increase in 12-month adjusted risk for a 4- versus 6-week interval between doses. Further analysis revealed those receiving their first RV5 dose at 3-4 and 5-7 weeks had 2.9% (95% CI = 0.8, 5.3) and 1.3% (95% CI = -0.3, 3.0), respectively, higher risk compared with those at 9-12 weeks. Those receiving their first dose at 8 weeks had the lowest risk (RD: -2.6% [95% CI = -5.4, -0.1]) compared with those at 9-12 weeks. CONCLUSIONS: A modest delay in rotavirus vaccination start and increase in interval between doses may be associated with lower severe rotavirus gastroenteritis risk in low- and middle-income countries.
RCT Entities:
BACKGROUND: Altering rotavirus vaccine schedules may improve vaccine performance in low- and middle-income countries. We analyzed data from clinical trials of the monovalent (RV1) and pentavalent (RV5) rotavirus vaccines in low- and middle-income countries to understand the association between vaccine dose timing and severe rotavirus gastroenteritis incidence. METHODS: We assessed the association between variations in rotavirus vaccine administration schedules and severe rotavirus gastroenteritis risk. We used the complement of the Kaplan-Meier survival estimator to estimate risk differences for different schedules. To adjust risk differences (RDs) for confounding, we calibrated estimates in the vaccinated arm using estimates from the placebo arm. RESULTS: There were 3,114 and 7,341 children included from the RV1 and RV5 trials, respectively. The 18-month adjusted severe rotavirus gastroenteritis risk was 4.0% (95% confidence interval [CI] = 1.1, 7.1) higher for those receiving their first RV5 dose at <6 versus ≥6 weeks. For RV1, there was a 4.0% (95% CI = 0.0, 8.2) increase in 12-month adjusted risk for a 4- versus 6-week interval between doses. Further analysis revealed those receiving their first RV5 dose at 3-4 and 5-7 weeks had 2.9% (95% CI = 0.8, 5.3) and 1.3% (95% CI = -0.3, 3.0), respectively, higher risk compared with those at 9-12 weeks. Those receiving their first dose at 8 weeks had the lowest risk (RD: -2.6% [95% CI = -5.4, -0.1]) compared with those at 9-12 weeks. CONCLUSIONS: A modest delay in rotavirus vaccination start and increase in interval between doses may be associated with lower severe rotavirus gastroenteritis risk in low- and middle-income countries.
Authors: Sasirekha Ramani; Nora Mamani; Rodolfo Villena; Ananda S Bandyopadhyay; Chris Gast; Alicia Sato; Daniel Laucirica; Ralf Clemens; Mary K Estes; Miguel L O'Ryan Journal: Pediatr Infect Dis J Date: 2016-10 Impact factor: 2.129
Authors: Joann F Gruber; Darcy A Hille; G Frank Liu; Susan S Kaplan; Micki Nelson; Michelle G Goveia; T Christopher Mast Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: Andrew Duncan Steele; Kathleen M Neuzil; Nigel A Cunliffe; Shabir A Madhi; Pieter Bos; Bagrey Ngwira; Desiree Witte; Stacy Todd; Cheryl Louw; Mari Kirsten; Sanet Aspinall; Leen Jan Van Doorn; Alain Bouckenooghe; Pemmaraju V Suryakiran; Htay Htay Han Journal: BMC Infect Dis Date: 2012-09-13 Impact factor: 3.090
Authors: Tessa Braeckman; Koen Van Herck; Nadia Meyer; Jean-Yves Pirçon; Montse Soriano-Gabarró; Elisabeth Heylen; Mark Zeller; Myriam Azou; Heidi Capiau; Jan De Koster; Anne-Sophie Maernoudt; Marc Raes; Lutgard Verdonck; Marc Verghote; Anne Vergison; Jelle Matthijnssens; Marc Van Ranst; Pierre Van Damme Journal: BMJ Date: 2012-08-08
Authors: K Zaman; Jessica A Fleming; John C Victor; Mohammad Yunus; Tajul Islam A Bari; Tasnim Azim; Mustafizur Rahman; Syed Mohammad Niaz Mowla; William J Bellini; Monica McNeal; Joseph P Icenogle; Ben Lopman; Umesh Parashar; Margaret M Cortese; A Duncan Steele; Kathleen M Neuzil Journal: J Infect Dis Date: 2016-01-27 Impact factor: 5.226
Authors: Edward P K Parker; Ira Praharaj; Anna Zekavati; Robin P Lazarus; Sidhartha Giri; Darwin J Operario; Jie Liu; Eric Houpt; Miren Iturriza-Gómara; Beate Kampmann; Jacob John; Gagandeep Kang; Nicholas C Grassly Journal: Vaccine Date: 2017-12-06 Impact factor: 3.641
Authors: Ernest O Asare; Mohammad A Al-Mamun; Monira Sarmin; A S G Faruque; Tahmeed Ahmed; Virginia E Pitzer Journal: Proc Biol Sci Date: 2022-06-08 Impact factor: 5.530